Patent intelligence · US
US 12378231
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof
Patent details — US 12378231
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 5, 2025
- Expiration
- Jul 31, 2045
- Applicant
- APOGEE PHARMACEUTICALS, INC.
- Claims
- 27
- CPC classes
- A61K, A61K31/4192, A61K31/454, A61K31/496
Quick answer
US 12378231 (Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof) is held by APOGEE PHARMACEUTICALS, INC.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- APOGEE PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/4192, A61K31/454, A61K31/496, A61K31/551, A61K45/06
More from APOGEE PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12410137
Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof
granted -
US 12358979
Antibodies that bind interleukin 13 and methods of use
granted -
US 8685936
Sphingosine kinase inhibitor prodrugs
granted -
US 8557800
Sphingosine kinase inhibitors
granted -
US 8063248
Sphingosine kinase inhibitors
granted -
US 7338961
Sphingosine kinase inhibitors
granted
Frequently asked questions
What is US patent 12378231?
US 12378231 (Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof) is held by APOGEE PHARMACEUTICALS, INC.. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12378231?
APOGEE PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 12378231 expire?
Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.